Bronchiectasis itself is not directly inherited as a single-gene condition. However, several hereditary disorders can cause bronchiectasis as a complication, making genetics a significant factor in who develops it. Cystic fibrosis alone accounts for nearly half of all bronchiectasis cases in the United States, and other inherited conditions like primary ciliary dyskinesia and immune deficiencies are leading causes in children. So while you won’t find a “bronchiectasis gene,” the condition frequently has genetic roots.
Genetic Conditions That Cause Bronchiectasis
The most common inherited causes fall into three categories: conditions that thicken mucus, conditions that impair the tiny hair-like structures responsible for clearing mucus from the lungs, and conditions that weaken the immune system. Each leads to the same end result through a different path: repeated lung infections that gradually damage and widen the airways beyond repair.
Cystic fibrosis (CF) is the single largest genetic contributor. It causes thick, sticky mucus to build up in the lungs, creating an environment where bacteria thrive. In the U.S., CF drives roughly half of all bronchiectasis cases. Most people with CF are diagnosed in childhood, but milder forms can go undetected into adulthood, particularly in people who have chronic sinus problems, digestive issues, or recurrent lung infections with specific bacteria like Pseudomonas or Staphylococcus.
Primary ciliary dyskinesia (PCD) is an autosomal recessive disorder, meaning a child must inherit a defective gene copy from both parents. In PCD, the motile cilia lining the airways either don’t move or are missing entirely. These cilia normally beat in coordinated waves to push mucus, bacteria, and debris up and out of the lungs. Without that clearance system, mucus pools in the airways, infections recur, and chronic inflammation gradually scars and widens the bronchial tubes into permanent bronchiectasis.
Common variable immunodeficiency (CVID) is the immune disorder most strongly linked to bronchiectasis. People with CVID produce inadequate antibodies, leaving them vulnerable to repeated respiratory infections. Studies estimate that 34 to 52% of people with CVID develop bronchiectasis. Those who do tend to experience faster declines in lung function, higher rates of annual respiratory infections, and a worse overall quality of life compared to CVID patients without bronchiectasis.
Less Common Hereditary Links
Alpha-1 antitrypsin deficiency, an inherited condition that primarily causes emphysema, also carries a bronchiectasis risk. In a study of patients with the most severe genetic form (called PiZZ), about 9% had bronchiectasis as their only lung finding on CT scan. Among the majority who had emphysema, an additional 27% also showed bronchiectasis. This overlap matters because bronchiectasis may need different treatment strategies than emphysema alone.
Mounier-Kuhn syndrome, a rare condition involving abnormal widening of the trachea and main airways, has been linked to possible autosomal recessive inheritance, though some researchers consider cases sporadic. The underlying problem appears to be a loss of elastic fibers and muscle tissue in the airway walls, which can be present from birth. The weakened walls lead to poor mucus clearance and recurrent infections, eventually progressing to bronchiectasis.
Congenital bronchiectasis, present from birth, results from genetic factors that disrupt how the lungs form during fetal development. This is distinct from the conditions above, where structurally normal lungs are damaged over time. It’s rare but worth noting because it represents a case where the bronchiectasis itself, not just a predisposing condition, is congenital.
How Often Is the Cause Genetic in Children vs. Adults?
In children, genetic and immune-related causes dominate. A study of childhood bronchiectasis found that post-infectious causes were the most common overall at 31%, but primary and secondary immunodeficiencies accounted for 19%, with congenital airway malformations adding another 13%. When you factor in cystic fibrosis and PCD, a substantial share of pediatric bronchiectasis traces back to an inherited condition.
In adults, the picture shifts. Most adult bronchiectasis diagnosed outside of CF clinics is post-infectious, meaning it developed after severe pneumonia, tuberculosis, or other lung infections rather than from a genetic defect. Less than 1% of adults in non-CF bronchiectasis clinics turn out to have undiagnosed cystic fibrosis. Still, a meaningful minority of adults have an underlying genetic cause that was simply never identified in childhood, which is why guidelines recommend testing for it.
When Genetic Testing Is Recommended
European Respiratory Society guidelines recommend that all newly diagnosed bronchiectasis patients undergo standardized testing to identify an underlying cause. For genetic conditions specifically, the triggers for testing include symptoms that started in childhood (regardless of when the diagnosis comes), chronic sinus disease with or without nasal polyps, male infertility, digestive problems like malabsorption or pancreatitis, and upper-lobe predominant bronchiectasis on imaging. All patients should be screened for immunodeficiency through blood antibody levels.
Testing for alpha-1 antitrypsin deficiency isn’t routine but is recommended when imaging shows emphysema at the base of the lungs or when airflow obstruction is unusually severe. CF and PCD screening is specifically indicated when symptoms began in childhood or when clinical features point in that direction.
Why Identifying a Genetic Cause Matters
For many people with bronchiectasis, the damage is already done and treatment focuses on the same core strategies regardless of cause: clearing mucus from the airways, managing bacterial infections, and reducing inflammation. But knowing whether a genetic condition is driving the disease can meaningfully change your care.
A cystic fibrosis diagnosis, even in adulthood, now opens the door to highly effective modulator therapies that target the underlying protein defect. These drugs have transformed outcomes for CF patients, which is why guidelines emphasize that these cases should not be missed.
Primary ciliary dyskinesia doesn’t yet have a targeted drug treatment, but identifying it leads to more intensive airway clearance regimens, better management of chronic sinus disease, fertility counseling (since the same cilia involved in lung clearance play a role in reproduction), and cardiac screening, since ciliary defects can cause the heart to form on the wrong side of the chest.
For immunodeficiency-related bronchiectasis, treatment with immunoglobulin replacement therapy can reduce the cycle of infection and inflammation that drives ongoing lung damage. Identifying CVID early may slow the progression of bronchiectasis and preserve lung function longer.
In contrast, when bronchiectasis results from a past infection with no underlying genetic condition, management focuses entirely on the “treatable traits” of the disease: keeping airways clear, controlling bacterial colonization, and dampening inflammation. There’s no upstream cause to address.